Radiolabeled Pertuzumab for Imaging of Human Epidermal Growth Factor Receptor 2 Expression in Ovarian Cancer.

Dawei Jiang,Hyung-Jun Im,Haiyan Sun,Hector F. Valdovinos,Christopher G. England,Emily B. Ehlerding,Robert J. Nickles,Dong Soo Lee,Steve Y. Cho,Peng Huang,Weibo Cai
DOI: https://doi.org/10.1007/s00259-017-3663-y
2017-01-01
Abstract:Human epidermal growth factor receptor 2 (HER2) is over-expressed in over 30% of ovarian cancer cases, playing an essential role in tumorigenesis and metastasis. Non-invasive imaging of HER2 is of great interest for physicians as a mean to better detect and monitor the progression of ovarian cancer. In this study, HER2 was assessed as a biomarker for ovarian cancer imaging using 64Cu-labeled pertuzumab for immunoPET imaging.
What problem does this paper attempt to address?